Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas

被引：11

作者：

Negaard, Helene F. S. ^{[1
,2
]}

Svennevig, Katja ^{[3
]}

Kolset, Svein Olav ^{[3
]}

Iversen, Nina ^{[4
]}

Lothe, Inger Marie Bowitz ^{[5
]}

Ostenstad, Bjorn ^{[6
]}

Sandset, Per Morten ^{[1
,2
]}

Iversen, Per Ole ^{[1
,3
]}

机构：

[1] Univ Oslo, Ulleval Hosp, Dept Haematol, N-0407 Oslo, Norway

[2] Univ Oslo, Fac Med, N-0407 Oslo, Norway

[3] Univ Oslo, Dept Nutr, N-0407 Oslo, Norway

[4] Univ Oslo, Ulleval Hosp, Dept Med Genet, N-0407 Oslo, Norway

[5] Univ Oslo, Ulleval Hosp, Dept Pathol, N-0407 Oslo, Norway

[6] Univ Oslo, Ulleval Hosp, Ctr Canc, N-0407 Oslo, Norway

来源：

LEUKEMIA & LYMPHOMA | 2009年 / 50卷 / 06期

关键词：

Angiogenesis; extracellular matrix; metalloproteinases; non-Hodgkin lymphoma; syndecan-1; FACTOR PATHWAY INHIBITOR-2; TISSUE FACTOR; METALLOPROTEINASE (MMP)-2; ANGIOGENESIS; GROWTH; CELLS; MMP-9; MALIGNANCIES; EXPRESSION; SYNDECAN-1;

D O I：

10.1080/10428190902889270

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bone marrow angiogenesis is increased in non-Hodgkin lymphomas (NHL). Compounds affecting extracellular matrix (ECM) may modify angiogenesis. Here we investigated ECM regulators in 48 unselected NHL patients compared with 35 controls. Untreated patients had elevated (P0.05) serum matrix metalloproteinase (MMP) 9 and tissue inhibitor of metalloproteinase (TIMP) 1, while MMP-2, TIMP-2 and syndecan-1 were not significantly different from controls. MMP-9 mRNA was significantly up-regulated in blood mononuclear cells, while mRNA expressions of the other ECM regulators were unaltered. We found strong correlations between mRNA expressions of both vascular endothelial growth factor and fibroblast growth factor 2, and MMP-9, TIMP-1 and TIMP-2. After therapy, serum MMP-2 increased while MMP-9 decreased (P0.05), the others being unchanged. Several compounds affecting ECM may be involved in angiogenic activity in NHL.

引用

页码：998 / 1004

页数：7

共 38 条

[21] Matrix metalloproteinases: multifunctional contributors to tumor progression
McCawley, LJ
Matrisian, LM
[J]. MOLECULAR MEDICINE TODAY, 2000, 6 (04): : 149 - 156
[22] Angiogenesis in hematologic malignancies
Moehler, TM
Ho, AD
Goldschmidt, H
Barlogie, B
[J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (03) : 227 - 244
[23] Angiogenesis and hemostasis in hematological neoplasias
Negaard, H
Dahm, A
Sandset, PM
Iversen, PO
Ostenstad, B
[J]. CURRENT DRUG TARGETS, 2005, 6 (06) : 681 - 699
[24] Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors
Negaard, H. F. S.
Iversen, N.
Bowitz-Lothe, I. M.
Sandset, P. M.
Steinsvik, B.
Ostenstad, B.
Iversen, P. O.
[J]. LEUKEMIA, 2009, 23 (01) : 162 - 169
[25] Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor
Negaard, Helene F. S.
Iversen, Per Ole
Ostenstad, Bjorn
Iversen, Nina
Holme, Pal A.
Sandset, Per Morten
[J]. THROMBOSIS AND HAEMOSTASIS, 2008, 99 (06) : 1040 - 1048
[26] Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials
Pavlaki, M
Zucker, S
[J]. CANCER AND METASTASIS REVIEWS, 2003, 22 (2-3) : 177 - 203
[27] Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma
Pennanen, Heli
Kuittinen, Outi
Turpeenniemi-Hujanen, Taina
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2008, 80 (01) : 46 - 54
[28] Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO
[29] 2-Y
[30] Matrix metalloproteinases and angiogenesis
Rundhaug, JE
[J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2005, 9 (02) : 267 - 285

← 1 2 3 4 →